mardi 31 juillet 2018

Onco Actu du 31 juillet 2018

1. Biologie

Liver cancer cell ‘switch’ found that could improve future therapies [Imperial College London]

Scientists Discover a Dynamic Cellular Defense Against Breast Cancer Invasion [Johns Hopkins]

3.1.1 Prévention - Tabac - e-cigs

E-cigarette maker Juul targeted teens with false claims of safety, lawsuit says [Washington Post]

4.2 Dép., diag. & prono. - Génome

At-Home Genetic Tests for Cancer: What You Need to Know [Dana-Farber Cancer Institute]

4.7 Dép., diag. & prono. - Col de l'utérus

FDA Approves Roche HPV Test for SurePath Collection Media [Genome Web]

Cervical screening issues causing delays for women in East [BBC News]

5. Traitements

Agios’s Schenkein: “It’s not one disease. Just like lung cancer’s not one disease” [The Cancer Letter]

OSU’s Byrd: “It’s becoming necessary to consult with an expert, because it is complicated, and things are moving” [The Cancer Letter]

New drugs and new ideas are transforming AML [The Cancer Letter]

5.1 Traitements - Pré-clinique

Breast cancers enlist the help of normal cells to help them spread and survive [Garvan Institute]

Cannabinoid improves survival rates of mice with pancreatic cancer [Queen Mary University of London]

5.12.6 Immunothérapies - AMM

European backing for Merck's Keytruda rubs salt in Bristol-Myers' wounds [FiercePharma]

European Medicines Agency Adopts Positive Opinion for KEYTRUDA® (pembrolizumab) Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer [merck]

5.2.1 Pharma - Partenariats

Lilly firms up cancer collaboration with Dana-Farber [FierceBiotech]

Lilly Announces Extension of Cancer Research Collaboration with Dana-Farber Cancer Institute [Lilly]

5.3 Traitements - FDA, EMA, NICE...

FDA outlines a laundry list of surrogate endpoints with an eye to expanding the roster for drug developers [EndPoints]

FDA will organize new review divisions around disease types, Gottlieb testifies [The Cancer Letter]

5.3.4 Traitements - AMM (FDA, EMA,...)

Progenics Pharmaceuticals Announces FDA Approval for AZEDRA® (iobenguane I 131) to Treat Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma [Progenics]

FDA approves cancer radiation drug Azedra, sending Progenics stock north [EndPoints]

FDA approves iobenguane I 131 for rare adrenal gland tumors [FDA]

6.1 Observation

UAB researcher finds risk of later death after donor blood, marrow transplant in childhood [University of Alabama at Birmingham]

6.5 Médecines alternatives

Complementary medicine use and cancer survival: A negative correlation [Respectful Insolence]

6.8 Communication

Angelina Jolie’s surgeon peddles misinformation about…breast cancer! [Science-based Medicine]

Problematic PR releases: Where’s the data? [HealthNewsReview]

6.9 Controverses

Richard Smith: Measuring research impact—all the rage but hard to get right [BMJ Blogs]